Science and Medicine Group

Instrument Business Outlook Volume 31 - Issue 21 16 Feb 2023

Report details
15 Figures
30 Tables

Global Business R&D Expenditures Bounce Back After COVID-19 Outbreak
- Pharma & Biotech
- Chemicals
Where Do Molecular Diagnostics Go After COVID-19?
- Infectious Diseases: HIV, STI and non-COVID Respiratory
- Inherited Diseases
- NAT Blood Screening: Continuing to Replace Immunoassays
- Vendors
Executive Briefing
- Danaher Expresses Interest in CDMO Company
- Waters Enters Light Scattering Market
- Biotage to Acquire Bioprocess Chromatography Provider
- Illumina Contests EU’s GRAIL Decision
- Danaher Announces Spin-Off’s Name
- Cytek Biosciences Buys DiaSorin’s Flow Cytometry Business
- Yokogawa Buys Technology for Polymerization Reaction Monitoring
- Azenta Adds to Automation Solutions
Fourth Quarter Results: Bio-Techne, QIAGEN, Sartorius and Shimadzu AMI
- Bio-Techne Produces Revenue Growth Despite Challenges
- QIAGEN’s Base Business Performs Well in 2022
  - Q4
  - FYE 2022
- Sartorius’ Revenue Growth Strong for Q4 and FY22
  - Q4
  - FYE 2022
- M&A Helps Shimadzu AMI’s Fiscal Third Quarter Sales
Market Profile: Spatial Omics
- Leading Vendors
- Largest Markets
- Average Instrument Cost
Industry Watch
- Biopharma: R&D Innovation rate declines
- Consumer: Tainted cough syrup
- Government & R&D: US FY23 science budget
Region Watch
- India: Latest budget release
- UK: Decline in biotech financing
- South Africa: R&D spending falls in 2021
News
- Broad-Based Companies
  - Company Announcements
  - New Product
- MS, LC/MS and GC/MS
  - Company Announcements
  - Product Introductions
  - Sales & Orders of Note
- Sequencing
  - Company Announcements
  - Product Introductions
  - Sales & Orders of Note
- Informatics
  - Company Announcements
  - Product Introductions
  - Sales & Orders of Note
Bottom Line

Attachments

IBO 021523 article.pdf

Instrument Business Outlook Volume 31 - Issue 21

16 Feb 2023

Request Access

Table of Contents

Global Business R&D Expenditures Bounce Back After COVID-19 Outbreak
- Pharma & Biotech
- Chemicals
Where Do Molecular Diagnostics Go After COVID-19?
- Infectious Diseases: HIV, STI and non-COVID Respiratory
- Inherited Diseases
- NAT Blood Screening: Continuing to Replace Immunoassays
- Vendors
Executive Briefing
- Danaher Expresses Interest in CDMO Company
- Waters Enters Light Scattering Market
- Biotage to Acquire Bioprocess Chromatography Provider
- Illumina Contests EU’s GRAIL Decision
- Danaher Announces Spin-Off’s Name
- Cytek Biosciences Buys DiaSorin’s Flow Cytometry Business
- Yokogawa Buys Technology for Polymerization Reaction Monitoring
- Azenta Adds to Automation Solutions
Fourth Quarter Results: Bio-Techne, QIAGEN, Sartorius and Shimadzu AMI
- Bio-Techne Produces Revenue Growth Despite Challenges
- QIAGEN’s Base Business Performs Well in 2022
  - Q4
  - FYE 2022
- Sartorius’ Revenue Growth Strong for Q4 and FY22
  - Q4
  - FYE 2022
- M&A Helps Shimadzu AMI’s Fiscal Third Quarter Sales
Market Profile: Spatial Omics
- Leading Vendors
- Largest Markets
- Average Instrument Cost
Industry Watch
- Biopharma: R&D Innovation rate declines
- Consumer: Tainted cough syrup
- Government & R&D: US FY23 science budget
Region Watch
- India: Latest budget release
- UK: Decline in biotech financing
- South Africa: R&D spending falls in 2021
News
- Broad-Based Companies
  - Company Announcements
  - New Product
- MS, LC/MS and GC/MS
  - Company Announcements
  - Product Introductions
  - Sales & Orders of Note
- Sequencing
  - Company Announcements
  - Product Introductions
  - Sales & Orders of Note
- Informatics
  - Company Announcements
  - Product Introductions
  - Sales & Orders of Note
Bottom Line